Amiloride derivatives block ion channel activity and enhancement of virus-like particle budding caused by HIV-1 protein Vpu.
about
Entry of feline calicivirus is dependent on clathrin-mediated endocytosis and acidification in endosomesTargeted infection of HIV-1 Env expressing cells by HIV(CD4/CXCR4) vectors reveals a potential new rationale for HIV-1 mediated down-modulation of CD4Vpu Protein: The Viroporin Encoded by HIV-1Relevance of Viroporin Ion Channel Activity on Viral Replication and PathogenesisComputational Docking Study of p7 Ion Channel from HCV Genotype 3 and Genotype 4 and Its Interaction with Natural CompoundsConformational changes induced by a single amino acid substitution in thetrans-membrane domain of Vpu: Implications for HIV-1 susceptibility to channel blocking drugsInhibitors of the influenza A virus M2 proton channel discovered using a high-throughput yeast growth restoration assayThe HIV-1 Vpu viroporin inhibitor BIT225 does not affect Vpu-mediated tetherin antagonismAntiviral efficacy of the novel compound BIT225 against HIV-1 release from human macrophages.Cation-selective ion channels formed by p7 of hepatitis C virus are blocked by hexamethylene amiloride.Modulation of influenza virus replication by alteration of sodium ion transport and protein kinase C activityNovel approaches to inhibiting HIV-1 replication.Functional domains within the human immunodeficiency virus type 2 envelope protein required to enhance virus production.Fidelity variants of RNA dependent RNA polymerases uncover an indirect, mutagenic activity of amiloride compounds.Requirements of the membrane proximal tyrosine and dileucine-based sorting signals for efficient transport of the subtype C Vpu protein to the plasma membrane and in virus release.The Vpu protein: new concepts in virus release and CD4 down-modulationTopology and biological function of enterovirus non-structural protein 2B as a member of the viroporin familyPotential new anti-human immunodeficiency virus type 1 compounds depress virus replication in cultured human macrophages.Viroporins.Oligomerization state and supramolecular structure of the HIV-1 Vpu protein transmembrane segment in phospholipid bilayersDeterminants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu proteinMolecular dynamics simulations reveal the HIV-1 Vpu transmembrane protein to form stable pentamers.Effects of ribavirin on the replication and genetic stability of porcine reproductive and respiratory syndrome virusBacteria-based analysis of HIV-1 Vpu channel activity.The Attenuation Phenotype of a Ribavirin-Resistant Porcine Reproductive and Respiratory Syndrome Virus Is Maintained during Sequential Passages in Pigs.Modulation of the severe CD4+ T-cell loss caused by a pathogenic simian-human immunodeficiency virus by replacement of the subtype B vpu with the vpu from a subtype C HIV-1 clinical isolateTherapies for coronaviruses. Part 2: Inhibitors of intracellular life cycle.Comparative NMR studies demonstrate profound differences between two viroporins: p7 of HCV and Vpu of HIV-1.Targeting human immunodeficiency virus type 1 assembly, maturation and budding.Current and future therapies for hepatitis C virus infection: from viral proteins to host targets.The antiviral compound BIT225 inhibits HIV-1 replication in myeloid dendritic cells.Viroporins, Examples of the Two-Stage Membrane Protein Folding Model.Hepatitis C virus p7-a viroporin crucial for virus assembly and an emerging target for antiviral therapy.Various plus unique: Viral protein U as a plurifunctional protein for HIV-1 replicationNovel Acylguanidine-Based Inhibitor of HIV-1.Mechanisms of Action of Novel Influenza A/M2 Viroporin Inhibitors Derived from Hexamethylene Amiloride.Hepatitis E virus ORF3 is a functional ion channel required for release of infectious particlesA Phase 1b/2a study of the safety, pharmacokinetics and antiviral activity of BIT225 in patients with HIV-1 infection.Amiloride derivatives inhibit coxsackievirus B3 RNA replication.Recruitment of the adaptor protein 2 complex by the human immunodeficiency virus type 2 envelope protein is necessary for high levels of virus release
P2860
Q24674235-36356525-E1F7-4164-A27E-921E4AA70C5FQ25257643-2A7A76ED-5834-482A-BB14-A00986A33A99Q26801489-2C563171-93B2-430F-8FF8-EB9F5D86DEE7Q26823195-6369B895-2F59-49ED-83FA-D163A4B28981Q27307600-8B8A2714-5E45-412C-8793-7FEDFD602AF3Q27647751-36264014-C574-4518-B764-98B006FEC089Q28485914-DF35AE54-C06C-42C6-A167-1B05406AA868Q28742774-57E16E9B-22D1-4506-84BA-1F6671FE3C2CQ30968332-1A8C1B58-3D92-4999-9679-EAED6651D67FQ31037469-A5986263-AA16-4E0A-AB8A-4348694AE896Q33347317-FFFD65AC-4208-44B5-92E3-16A55B366A4CQ33624690-0A154225-C52C-4BBA-B6D3-3E06F3F7883AQ33737672-9828C617-8DA1-4338-A9EE-8122055A2E69Q33741951-2E5E9E89-DCD9-4E5E-B662-65730AC8C49DQ33926185-29C2775C-9A8C-49F0-A571-7890266C6B67Q34021500-BF376509-F8FE-4DC3-8F0B-305869A57560Q34136039-06769E49-9C98-4C7D-842E-0815EB94BF00Q34141302-09594BA4-A894-4C47-A0F2-B8B45E782439Q34230206-07978EF4-B000-4454-8236-2481BD2A2FAEQ34389186-F603B73A-3CDC-48A4-97C5-E9075B9AD025Q34416492-87548B34-3FCA-4C27-BA3A-E5168103B6AFQ35040322-95CB3DF9-57CF-4DE6-BC7E-736B7A0DA9ECQ35131997-D2478E15-4BBA-402B-AB7A-0989AD9F275CQ35291655-14836D09-9184-46A7-B5A8-58F3923C7041Q36811916-B6B358CD-2739-498E-99C7-7C4B373F40A4Q37307754-3A90737B-8CEE-4E35-AC6E-6B078A5ED2E8Q37481314-A75FBDCA-D9D5-43BD-9F93-DAB36AAD1B98Q37781488-1F43C0B0-1945-49C2-8B91-F85838D6A337Q37928913-2E031657-4D89-46CC-84E7-AA8E104DAC6EQ38131681-1D4D0197-AC12-4FAE-B039-E77C93FD8FF7Q38281910-3C5836BB-8158-4F03-9182-645E6A70930BQ38541409-B4B7B937-7A25-4459-8FC2-091AD13E5C32Q38615924-678B656C-2CA7-4A10-91CE-000EDC970154Q38739273-306997A5-93A5-4230-AA49-ED267DEFC401Q38752518-AB16B0D1-90A9-43E8-BFDB-8A222C5D172FQ38770144-42EADC59-8E9F-4F91-953F-84E85EB63DA7Q39016100-FDAC1163-3DF2-4BF5-9040-3A5649FD40E7Q40889648-FF54FAA9-AE2B-4903-BE24-D5D7DC17CEB7Q41914133-02CB328F-A30F-47F5-AC86-0EF88EF3BB2AQ42133593-2D554F2D-83B3-469B-B18C-8CD6AB094997
P2860
Amiloride derivatives block ion channel activity and enhancement of virus-like particle budding caused by HIV-1 protein Vpu.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Amiloride derivatives block io ...... g caused by HIV-1 protein Vpu.
@en
Amiloride derivatives block io ...... g caused by HIV-1 protein Vpu.
@nl
type
label
Amiloride derivatives block io ...... g caused by HIV-1 protein Vpu.
@en
Amiloride derivatives block io ...... g caused by HIV-1 protein Vpu.
@nl
prefLabel
Amiloride derivatives block io ...... g caused by HIV-1 protein Vpu.
@en
Amiloride derivatives block io ...... g caused by HIV-1 protein Vpu.
@nl
P2093
P356
P1476
Amiloride derivatives block io ...... g caused by HIV-1 protein Vpu.
@en
P2093
Gary D Ewart
Graeme B Cox
Kerry Mills
Peter W Gage
P2888
P356
10.1007/S002490100177
P577
2002-03-01T00:00:00Z